Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
In Vivo Pharmacokinetic Assays

In Vivo Pharmacokinetic Assays

Medicilon has rich experience in pharmacokinetics research. We offer a broad spectrum of high quality of services involving all micromolecule and macromolecule (protein and antibody), with service contents including in vitro ADME, in vivo pharmacokinetics and bioanalysis. The test subjects involved include non-human primates, dogs, rats/mice, rabbits and guinea pigs. Among them, the non-human primate experimental platform and the isotope platform for protein/antibody have been recognized as important laboratory platforms by Shanghai Municipal People's Government.
Medicilon icon-diamond.pngServices
  • Haemodynamics ResearchTissue Distribution ResearchExcretion ResearchMaterial BalanceBlood Brain BarrierADC pharmacokinetic evaluation, etc.
Due to complex compositions, the PK characteristics of ADC must be evaluated by multiple analytes. Therefore, the difficulty of analysis is increased. In the in vivo assay of ADC, we have provided a variety of quality testing methos for various ADC component analytes. By analyzing plasma/serum samples collected from animals, we provide our clients with reliable and quality PK data.
DeterminandDescriptionTypical analysis method
Conjugated AntibodyAntibody conjugated to at least one drugLBA
Total AntibodyFully conjugated, partially conjugated and unconjugated antibodiesLBA
Small MoleculesFree or diluted drug micromolecules and their metabolitesLC-MS/MS
ADAAntibodies that can specifically bind ADC molecules and their partial structuresLBA
In the meantime, Medicilon has introduced an animal in vivo PET/CT/MR molecular imaging system. Through the system, the delicate and complex physiological and metabolic processes in organisms can be observed. The PET research with radio-tracer label can ensure quantitative evaluation of the pharmacokinetics and metabolism of drugs. Combined with efficacy data including ethology performance, the pharmacokinetics PET researcher can establish the dose-efficacy relationship and determine the dose while tracking the regional distribution of drugs in target tissues.
Medicilon icon-notebook.pngEvaluation performance
  • Our Preclinical Pharmacokinetics Department can complete nearly 1,000 single pharmacokinetic researches in vivo and nearly 200 complete pharmacokinetic researches in accordance with the filing every year.The research categories involve micromolecule drugs, bio-tech-based drugs and natural product drugs.The contents involved in evaluation include but are not limited to haemodynamics, tissue distribution, rxcretion and material balance.Medicilon have a research license for radioisotopes (125I, 14 C, 3H). The license is for material balance and tissue distribution researches.
Medicilon icon-bulb.pngSoftware
  • WinNolin and WastonLim are used for calculation and processing of pharmacokinetic research data and management of analytical laboratory.
  • What is Caco-2 Cell Model?

    The Caco-2 cell line is a human colon adenocarcinoma epithelial cell that can differentiate itself into a monolayer similar to a mature human small intestinal epithelial cell.

  • What are the Ideal DMPK Properties?

    (1) Complete absorption (passive absorption is better), bioavailability > 50% and small variation;

    (2) AUC is proportional to dose, and PK/PD correlation is clear;

    (3) Quickly reach the target organ and do not accumulate outside the target organ;

    (4) PPB<90%, not affected by concentration and time;

    (5) Plasma clearance CL<30%Qn, cleared through various routes;

    (6) Age, race, gender, disease state, etc. have little effect on CL;

    (7) metabolite quantity is low and no reactive metabolites are produced;

    (8) Does not inhibit or induce major drug metabolizing enzymes and transporters, and is not affected by food; 

    (9) T1/2>6hr in human body, which can reduce the dosing frequency and improve the compliance.

  • What is the Explanation for the Clearance (CL) > Hepatic Blood Flow (Qh) in the In Vivo PK Test in Animals?

    (1) The liver is the main organ of drug metabolism, but not the only way of drug elimination. There is also renal elimination, etc.

    (2) The drug is unstable in the blood, and the clearance of the drug does not have a hepatic effect.

    (3) In some cases, when the drug concentration in red blood cells is much higher than that in plasma, the calculation of proper clearance cannot be approximated by the drug concentration in plasma.

    (4) In individual cases, metabolism or uptake by the lungs occupies a significant role.

  • What Should Explain Bioavailability F > 100% in Animals' In Vivo PK Test?

    (1) Dose deviation due to administration error.

    (2) Nonlinear pharmacokinetics (Nonlinear PK).

    (3) High bioavailability and individual variability in the DMPK properties of the drug, with IV and PO, given to different groups of animals.

    (4) Overestimation of PO AUC or underestimation of IV AUC due to unreasonable sampling points.

    (5) IV samples were left for extended periods, and compounds were unstable in plasma.

    (6) When administered as a racemate, the faster-clearing enantiomer is converted to the slower-clearing enantiomer in the GI tract.

Relevant laboratories
  • Pharmacokinetics
  • Immunoassay Platform
  • Pharmacokinetic Instruments
  • isotope
  • Electrochemiluminescence instrument
  • high-speed centrifuge
  • Shimadzu UV Analyzer
  • Clinical testing equipment
  • Pharmacokinetics refrigerator
  • tissue embedding machine
  • LC-MS-MS
  • Tissue Dehydrator
  • Ultrasonic Disintegrator
Relevant articles